Peroxisomal β-oxidation and steatohepatitis

Seminars in Liver Disease

Volumn 21, Issue 1, 2001, Pages 43-55

  Rao, M S ^a   Reddy, J K ^a  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

Fatty acid oxidation; Microsomal oxidation; Peroxisomal acyl CoA oxidase deficiency; Peroxisomal and mitochondrial oxidation; Peroxisome proliferator activated receptors; PPAR and AOX double nulls; PPAR deficiency; Spontaneous peroxisome proliferation; Steatohepatitis

Indexed keywords

ACYL COENZYME A DEHYDROGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ADRENOLEUKODYSTROPHY; ANIMAL MODEL; CHONDRODYSPLASIA PUNCTATA; DIET RESTRICTION; ENZYME DEFICIENCY; FATTY ACID OXIDATION; FATTY LIVER; HEPATITIS; HUMAN; KNOCKOUT MOUSE; LIVER MICROSOME; MITOCHONDRIAL RESPIRATION; NONHUMAN; PEROXISOME; PRIORITY JOURNAL; REVIEW; ZELLWEGER SYNDROME;

EID: 0035082455     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-12928     Document Type: Review

References (68)

1. Coordinate control of intermediary metabolism in rat liver by the insulin/glucagon ratio during starvation and after glucose refeeding. Regulatory significance of long-chain acyl-CoA and cyclic AMP
2. Regulation of nutrient metabolism and energy expenditure
3. Mammalian mitochondrial β-oxidation
4. The role of the liver in metabolic homeostasis: Implications for inborn errors of metabolism
5. Molecular basis of inherited medium-chain acyl-CoA dehydrogenase deficiency causing sudden child death
6. Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting
7. A critical role for the peroxisome proliferator-activated receptor α (PPARα) in the cellular fasting response: The PPARα-null mouse as a model of fatty acid oxidation disorders
8. Peroxisome proliferator-activated receptor α controls the hepatic CYP4A induction adaptive response to starvation and diabetes
9. Defect in peroxisome proliferator-activated receptor α-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting
10. Developmental, nutritional, and hormonal regulation of tissue-specific expression of the genes encoding various acyl-CoA dehydrogenases and α-subunit of electron transfer flavoprotein in rat
11. Peroxisomal lipid metabolism
12. Peroxisomal β-oxidation enzymes
13. Isolation, complementary DNA sequence, and regulation of rat hepatic lauric acid ω-hydroxylase (cytochrome P450LAw): Identification of new cytochrome P-450 gene family
14. Fatty-acid metabolism and the pathogenesis of hepatocellular carcinoma: Review and hypothesis
15. Omega-hydroxyceramides are required for corneocyte lipid envelope (CLE) formation and normal epidermal permeability barrier function
16. Non-alcoholic steatohepatitis: Another disease of affluence
17. Acute hepatic failure and defective fatty acid transport: Clinical proof of a physiologic hypothesis
18. Steatohepatitis: A tale of two "hits"?
19. Metabolic and nutritional considerations in nonalcoholic fatty liver
20. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
21. Peroxisome proliferator-activated receptors: Nuclear control of metabolism
22. Peroxisome proliferator-activated receptors, coactivators, and downstream targets
23. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α (PPARα)
24. Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators
25. Hepatocellular and hepatic peroxisomal alterations in mice with a disrupted peroxisomal fatty acyl-coenzyme A oxidase gene
26. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase
27. Peroxisomal and mitochondrial fatty acid β-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor α and peroxisomal fatty acyl-CoA oxidase
28. Liver disturbances in obesity and diabetes mellitus
29. Roles of PPARs in health and disease
30. A fatty acyl-CoA oxidizing system in rat liver peroxisomes; enhancement by clofibrate, a hypolipidemic drug
31. Molecular characterization of the human peroxisomal branched-chain acyl-CoA oxidase: cDNA cloning, chromosomal assignment, tissue distribution, and evidence for the absence of the protein in Zellweger syndrome
32. Inactivation of the peroxisomal multifunctional protein-2 in mice impedes the degradation of not only 2-methyl-branched fatty acids and bile acid intermediates but also of very long chain fatty acids
33. Transcriptional regulation of peroxisomal fatty acyl-CoA oxidase and enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase in rat liver by peroxisome proliferators
34. Clofibrate-inducible rat hepatic P450s IVA1 and IVA3 catalyze the omega-and (omega-1)-hydroxylation of fatty acids and the omega-hydroxylation of prostaglandins E1 and F2 alpha
35. The peroxisome proliferator-activated receptor mediates the induction of CYP4A6, a cytochrome P450 fatty acid ω-hydroxylase, by clofibric acid
36. Hydrogen peroxide generation in peroxisome proliferator-induced oncogenesis
37. Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR) gamma gene: Alternative promoter use and different splicing yield two mPPAR gamma isoforms
38. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors
39. Hypolipidemic hepatic peroxisome proliferators form a novel class of chemical carcinogens
40. Hepatocarcinogenesis of peroxisome proliferators
41. Mechanism of action of the nongenotoxic peroxisome proliferators: Role of peroxisome proliferator-activated receptor α
42. Central role of PPARα in the mechanism of action of hepatocarcinogenic peroxisome proliferators
43. Peroxisome proliferator activated receptor-α expression in human liver
44. PPARγ, the ultimate thrifty gene
45. Adipogenesis and obesity: Rounding out the big picture
46. PPARγ is required for placental, cardiac, and adipose tissue development
47. PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance
48. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs
49. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(δ)
50. Isolation of the human peroxisomal acyl-CoA oxidase gene: Organization, promoter analysis, and chromosomal localization
51. Structure and expression of the genes encoding peroxisomal β-oxidation enzymes
52. Identification of a peroxisome proliferator-responsive element upstream of the human peroxisomal fatty acyl coenzyme A oxidase gene
53. Large deletion of the peroxisomal acyl-CoA oxidase gene in pseudoneonatal adrenoleukodystrophy
54. Novel subtype of peroxisomal acyl-CoA oxidase deficiency and bifunctional enzyme deficiency with detectable enzyme protein: Identification by means of complementation analysis
55. Peroxisomal disorders: A review
56. Three for the price of one knockout: A mouse model of a congenital peroxisomal disorder, steatohepatitis, and hepatocarcinogenesis
57. Glu-320 and Asp-323 are determinants of the CYP4A1 hydroxylation regiospecificity and resistance to inactivation by 1-aminobenzotriazole
58. Kinetics of cytochrome P450 2E1-catalyzed oxidation of ethanol to acetic acid via acetaldehyde
59. Diagnosis and interpretation of steatosis and steatohepatitis
60. Absence of spontaneous peroxisome proliferation in enoyl-CoA hydratase/L-3-hydroxyacyl-CoA dehydrogenase-deficient mouse liver
61. Defective peroxisomal catabolism of branched fatty acyl coenzyme A in mice lacking the sterol carrier protein-2/sterol carrier protein-x gene function
62. Effect of Reye's syndrome serum on isolated chinchilla liver mitochondria
63. Disorders of the mitochondria
64. Cellular signals in alcohol-induced liver injury: A review
65. Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis
66. A truncated human peroxisome proliferator-activated receptor alpha splice variant with dominant negative activity
67. A mouse model for X-linked adrenoleukodystrophy